Preventing Recurrence After Liver Cancer Surgery: What the IMbrave050 Trial Means for You

If you or someone you love has recently undergone surgery or ablation for hepatocellular carcinoma (HCC), the most common form of primary liver cancer, you have already been through a great deal — scans, decisions, the procedure itself, and the relief of hearing that the visible tumor is gone. But for many patients, a quieter worry follows close behind: will it come back? I hear this question in clinic almost every week, and for good reason. Recurrence after curative-intent surgery or ablation is unfortunately common in HCC, and until recently we had no proven medical treatment to give afterward to lower that risk — we could only watch closely and hope. That is why I am encouraged by the updated results of the IMbrave050 trial, published in the Journal of Hepatology in 2026, building on findings first presented at the American Society of Clinical Oncology (ASCO) annual meeting. This trial does not apply to every liver cancer patient, but for those with high-risk disease, it is one of the most meaningful steps forward we have seen in years.

Why Recurrence Is the Hardest Part of Liver Cancer Care

Removing or destroying a liver tumor through surgery or ablation is a major achievement, but it is not always the end of the story. HCC has a well-known tendency to recur, either in a different part of the liver or, less commonly, elsewhere in the body. Certain features identified at diagnosis or surgery — larger tumor size, multiple tumors, invasion of blood vessels by the tumor, or a more aggressive tumor grade — place patients into a "high-risk" category, meaning their chance of recurrence is higher than average. For these patients specifically, doctors have long wanted an "adjuvant" therapy: a treatment given after surgery, when no visible cancer remains, aimed at mopping up microscopic disease before it can grow back. Despite years of research, no adjuvant treatment had been proven to work for high-risk HCC — until this trial.

What the IMbrave050 Trial Tested

IMbrave050 is a Phase 3 clinical trial, the type of rigorous, large-scale study needed before a treatment can be considered a genuine advance. It enrolled patients with high-risk HCC who had already undergone curative-intent surgical resection or ablation — meaning their visible tumor had already been successfully removed or destroyed. The question the trial asked was simple but important: if we add immunotherapy afterward, can we prevent the cancer from returning, compared with simply monitoring patients closely?

Patients were assigned to one of two paths. One group received atezolizumab combined with bevacizumab — a combination that pairs a PD-L1 checkpoint inhibitor (a drug that helps the immune system recognize and attack cancer cells) with an anti-VEGF antibody (a drug that blocks blood vessel growth that tumors depend on). This same combination is already widely used to treat advanced, unresectable HCC, so its safety profile in liver cancer patients is well understood. In this trial, it was given every three weeks for up to one year, or seventeen treatment cycles. The other group underwent active surveillance — close monitoring with imaging and follow-up, but no additional drug therapy — also for one year.

What the Results Showed

The trial met its primary goal: patients who received the combination therapy had a 28% reduction in the risk of cancer recurrence or death compared with patients who were simply monitored. At a follow-up point of 17.4 months, the median recurrence-free survival — the point at which half of patients had experienced a recurrence — had not yet been reached in either group. In plain terms, more than half of patients in both groups remained recurrence-free at that stage of follow-up, but the treated group was doing significantly better on a statistical basis, which is what allowed the trial to reach its conclusion earlier than originally planned.

One honest and important point: overall survival data — meaning whether patients treated with this combination ultimately live longer, not just longer without recurrence — are not yet mature. Because the trial reached its primary endpoint sooner than expected, we simply need more time and longer follow-up before we can say with confidence whether this recurrence benefit will also translate into a clear survival advantage. This is not a reason for concern, but it is an important nuance I want you to understand rather than overstate.

Weighing the Benefits Against the Risks

No treatment is without cost, and this one is no exception. Serious, grade 3–4 treatment-related side effects occurred in about 35% of patients receiving the combination therapy, and serious adverse events of any kind occurred in about 13%. There was, sadly, one treatment-related death, in 0.6% of patients. These are meaningful risks, and they underscore why adjuvant immunotherapy is not automatically right for every high-risk patient. Some will feel the recurrence-risk reduction is well worth the potential side effects; others, depending on their overall health and priorities, may reasonably choose close surveillance instead. This decision should never be made in isolation — it deserves a thoughtful conversation with your liver surgeon and oncology team, ideally as part of a multidisciplinary liver cancer program.

The Bottom Line

For patients with high-risk hepatocellular carcinoma who have already undergone curative-intent surgery or ablation, the updated IMbrave050 results are genuinely encouraging: this is the first therapy to show a proven reduction in recurrence risk in this setting, cutting the relative risk of recurrence or death by 28%. It is not a treatment for everyone with liver cancer, it carries real side-effect risks, and we are still awaiting mature survival data. But for the right patient, discussed with a specialist familiar with your history and risk factors, this is a meaningful new option where, until now, we had none. If you have recently had liver cancer surgery or ablation and were told you are at higher risk of recurrence, I encourage you to raise this trial at your next visit so we can discuss whether it might be right for you.